Powles T, et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). ASCO-GU 2019, abstract 545.
Afatinib gevolgd door osimertinib bij EGFR-gemuteerd NSCLC
okt 2018 | Longoncologie